Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Cardiovascular Imaging Reports
Published in: Current Cardiovascular Imaging Reports 1/2010

01-02-2010

Molecular MRI of Atherosclerosis

Authors: Victoria E. L. Young, Tjun Y. Tang, Umar Sadat, Jonathan H. Gillard

Published in: Current Cardiovascular Imaging Reports | Issue 1/2010

Login to get access

Abstract

High-resolution MRI is an effective imaging tool for the assessment of atherosclerotic plaques. Although it has been used successfully for the morphological characterization of the atherosclerotic tissue, our ongoing quest to understand the pathobiology of atherogenesis has led to its use in imaging various biological factors involved in plaque initiation, progression, disruption, and regression. Imaging at the molecular and cellular level can play a pivotal role in the diagnosis of atherosclerosis at a preclinical stage and can also enable us to monitor the efficacy of novel anti-atherogenic treatments at the molecular level. This review discusses various methods of molecular MRI for atherosclerosis.
Literature
1.
2.
Libby P: The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 2008, 263:517–527.CrossRefPubMed
3.
Loftus IM, Naylor AR, Bell PR, Thompson MM: Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 2002, 89:680–694.CrossRefPubMed
4.
Ruehm SG, Corot C, Vogt P, et al.: Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 2001, 103:415–422.PubMed
5.
Yancy AD, Olzinski AR, Hu TC, et al.: Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling. J Magn Reson Imaging 2005, 21:432–442.CrossRefPubMed
6.
Herborn CU, Vogt FM, Lauenstein TC, et al.: Magnetic resonance imaging of experimental atherosclerotic plaque: comparison of two ultrasmall superparamagnetic particles of iron oxide. J Magn Reson Imaging 2006, 24:388–393.CrossRefPubMed
7.
Hyafil F, Laissy JP, Mazighi M, et al.: Ferumoxtran-10-enhanced MRI of the hypercholesterolemic rabbit aorta: relationship between signal loss and macrophage infiltration. Arterioscler Thromb Vasc Biol 2006, 26:176–181.CrossRefPubMed
8.
Trivedi RA, Mallawarachi CU, King-Im JM, et al.: Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol 2006, 26:1601–1606.CrossRefPubMed
9.
Kooi ME, Cappendijk VC, Cleutjens KB, et al.: Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003, 107:2453–2458.CrossRefPubMed
10.
Trivedi RA, U-King-IM JM, Graves MJ, et al.: In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 2004, 35:1631–1635.CrossRefPubMed
11.
Howarth SP, Tang TY, Trivedi R, et al.: Utility of USPIO-enhanced MR imaging to identify inflammation and the fibrous cap: a comparison of symptomatic and asymptomatic individuals. Eur J Radiol 2009, 70:555–560.CrossRefPubMed
12.
Tang TY, Howarth SP, Miller SR, et al.: Comparison of the inflammatory burden of truly asymptomatic carotid atheroma with atherosclerotic plaques contralateral to symptomatic carotid stenosis: an ultra small superparamagnetic iron oxide enhanced magnetic resonance study. J Neurol Neurosurg Psychiatry 2007, 78:1337–1343.CrossRefPubMed
13.
Tang TY, Patterson AJ, Miller SR, et al.: Temporal dependence of in vivo USPIO-enhanced MRI signal changes in human carotid atheromatous plaques. Neuroradiology 2009, 51:457–465.CrossRefPubMed
14.
Tang T, Howarth SP, Miller SR, et al.: Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke 2006, 37:2266–2270.CrossRefPubMed
15.
Crowe L: Ex vivo MR imaging of atherosclerotic rabbit aorta labelled with USPIO: enhancement of iron loaded regions in UTE imaging. Proc Int Soc Mag Reson Med 2005, 13:115.
16.
• Tang TY, Howarth SP, Miller SR, et al.: The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009, 53:2039–2050. This article demonstrates the impact these techniques can have on disease assessment and monitoring within a short timescale.CrossRefPubMed
17.
Mani V, Briley-Saebo KC, Itskovich VV, et al.: Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T. Magn Reson Med 2006, 55:126–135.CrossRefPubMed
18.
Saleh A, Schroeter M, Jonkmanns C, et al.: In vivo MRI of brain inflammation in human ischaemic stroke. Brain 2004, 127:1670–1677.CrossRefPubMed
19.
Frias JC, Williams KJ, Fisher EA, Fayad ZA: Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004, 126:16316–16317.CrossRefPubMed
20.
Cormode DP, Chandrasekar R, Delshad A, et al.: Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. Bioconjug Chem 2009, 20:937–943.CrossRefPubMed
21.
Chen W, Vucic E, Leupold E, et al.: Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging 2008, 3:233–242.CrossRefPubMed
22.
Li H, Gray BD, Corbin I, et al.: MR and fluorescent imaging of low-density lipoprotein receptors. Acad Radiol 2004, 11:1251–1259.CrossRefPubMed
23.
Nahrendorf M, Jaffer FA, Kelly KA, et al.: Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006, 114:1504–1511.CrossRefPubMed
24.
Tsourkas A, Shinde-Patil VR, Kelly KA, et al.: In vivo imaging of activated endothelium using an anti-VCAM-1 magneto-optical probe. Bioconjug Chem 2005, 16:576–581.CrossRefPubMed
25.
Radermacher KA, Beghein N, Boutry S, et al.: In vivo detection of inflammation using pegylated iron oxide particles targeted at E-selectin: a multimodal approach using MR imaging and EPR spectroscopy. Invest Radiol 2009, 44:398–404.CrossRefPubMed
26.
Boutry S, Laurent S, Elst LV, Muller RN: Specific E-selectin targeting with a superparamagnetic MRI contrast agent. Contrast Media Mol Imaging 2006, 1:15–22.CrossRefPubMed
27.
Gustafsson B, Youens S, Louie AY: Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation. Bioconjug Chem 2006, 17:538–547.CrossRefPubMed
28.
Mulder WJ, Strijkers GJ, Briley-Saboe KC, et al.: Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med 2007, 58:1164–1170.CrossRefPubMed
29.
Lipinski MJ, Frias JC, Amirbekian V, et al.: Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc Imaging 2009, 2:637–647.CrossRefPubMed
30.
Lipinski MJ, Amirbekian V, Frias JC, et al.: MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med 2006, 56:601–610.CrossRefPubMed
31.
Amirbekian V, Lipinski MJ, Briley-Saebo KC, et al.: Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A 2007, 104:961–966.CrossRefPubMed
32.
Ronald JA, Chen JW, Chen Y, et al.: Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation 2009, 120:592–599.CrossRefPubMed
33.
Amirbekian V, Aguinaldo JG, Amirbekian S, et al.: Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology 2009, 251:429–438.CrossRefPubMed
34.
Burtea C, Laurent S, Lancelot E, et al.: Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques. Mol Pharm 2009, 6:1903–1919.CrossRefPubMed
35.
Smith BR, Heverhagen J, Knopp M, et al.: Localization to atherosclerotic plaque and biodistribution of biochemically derivatized superparamagnetic iron oxide nanoparticles (SPIONs) contrast particles for magnetic resonance imaging (MRI). Biomed Microdevices 2007, 9:719–727.CrossRefPubMed
36.
van Tilborg GA, Mulder WJ, Chin PT, et al.: Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug Chem 2006, 17:865–868.CrossRefPubMed
37.
von Zur Muhlen C, von Elverfeldt D, Bassler N, et al.: Superparamagnetic iron oxide binding and uptake as imaged by magnetic resonance is mediated by the integrin receptor Mac-1 (CD11b/CD18): implications on imaging of atherosclerotic plaques. Atherosclerosis 2007, 193:102–111.
38.
Cyrus T, Abendschein DR, Caruthers SD, et al.: MR three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles. J Cardiovasc Magn Reson 2006, 8:535–541.CrossRefPubMed
39.
Anderson SA, Rader RK, Westlin WF, et al.: Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med 2000, 44:433–439.CrossRefPubMed
40.
Langheinrich AC, Kampschulte M, Buch T, Bohle RM: Vasa vasorum and atherosclerosis-quid novi? Thromb Haemost 2007, 97:873–879.PubMed
41.
Mulder WJ, Castermans K, van Beijnum JR, et al.: Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis 2009, 12:17–24.CrossRefPubMed
42.
Botnar RM, Perez AS, Witte S, et al.: In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation 2004, 109:2023–2029.CrossRefPubMed
43.
Botnar RM, Buecker A, Wiethoff AJ, et al.: In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation 2004, 110:1463–1466.CrossRefPubMed
44.
Sirol M, Aguinaldo JG, Graham PB, et al.: Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. Atherosclerosis 2005, 182:79–85.CrossRefPubMed
45.
Sirol M, Fuster V, Badimon JJ, et al.: Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation 2005, 112:1594–1600.CrossRefPubMed
46.
Flacke S, Fischer S, Scott MJ, et al.: Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001, 104:1280–1285.CrossRefPubMed
47.
Morawski AM, Winter PM, Yu X, et al.: Quantitative “magnetic resonance immunohistochemistry” with ligand-targeted (19)F nanoparticles. Magn Reson Med 2004, 52:1255–1262.CrossRefPubMed
48.
• Spuentrup E, Botnar RM, Wiethoff AJ, et al.: MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol 2008, 18:1995–2005. This article illustrates a molecular magnetic resonance technique that has been translated from in vitro/animal work to a human study. Most techniques, as illustrated by this article, are still in the early stages of investigation.CrossRefPubMed
49.
Miserus RJ, Herias MV, Prinzen L, et al.: Molecular MRI of early thrombus formation using a bimodal alpha2-antiplasmin-based contrast agent. JACC Cardiovasc Imaging 2009, 2:987–996.CrossRefPubMed
50.
Chaubet F, Bertholon I, Serfaty JM, et al.: A new macromolecular paramagnetic MR contrast agent binds to activated human platelets. Contrast Media Mol Imaging 2007, 2:178–188.CrossRefPubMed
Metadata
Title
Molecular MRI of Atherosclerosis
Authors
Victoria E. L. Young
Tjun Y. Tang
Umar Sadat
Jonathan H. Gillard
Publication date
01-02-2010
Publisher
Current Science Inc.
Published in
Current Cardiovascular Imaging Reports / Issue 1/2010
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-010-9006-z

Other articles of this Issue 1/2010

Current Cardiovascular Imaging Reports 1/2010 Go to the issue

OriginalPaper

Optical Molecular Imaging of Inflammation and Calcification in Atherosclerosis

Clinical Trial Report

The ATHEROMA Study: Rapid Anti-inflammatory Effects of High-Dose Statin Pharmacotherapy Illuminated by Molecular MRI

OriginalPaper

Ultrasound Molecular Imaging of Cardiovascular Disease

OriginalPaper

Molecular and Microstructural Imaging of the Myocardium

OriginalPaper

Nanomedicine and Cardiovascular Disease

OriginalPaper

Molecular Imaging of Thrombosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits